13 reports

Two biosimilar approvals have been withdrawn; one for filgrastim in April 2011 and one for somatropin in May 2012, leaving a total of ## biosimilars approved for use in Europe.

  • Insulin
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited
  • ROLE IN THE BIOSIMILARS INDUSTRY
  • CORPORATE ANALYSIS

HENCE, PEG-FILGRASTIM HAS A DISTINCT ADVANTAGE IN TERMS OF PATIENT SAFETY AGAINST FILGRASTIM.

  • Insulin
  • United States
  • Hospira, Inc.
  • Roche Group
  • Sandoz Inc.

FILGRASTIM ##. ##. ##.

  • Insulin
  • North America
  • United States
  • Market Size
  • Sandoz Inc.

MARKET ##.

  • Insulin
  • Vaccine
  • APAC
  • World
  • Market Size

QU=NEULASTA+FILGRASTIM& KID=##& T=NEULASTA& F=DRUGS& NEWS=##& PAGE=## ## SOURCE: HTTPS:/ / WWW. CDC. GOV/ H##N##FLU/ VACCINATION/ SYRINGES_QA. HTM ## SMARTJECT® IS A REGISTERED TRADEMARK OF JOHNSON & JOHNSON ## SOURCE: HTTP:/ / PHARMACY

  • Insulin
  • Debiotech S.A.
  • Medtronic, Inc.
  • Roche Group
  • West Pharmaceutical Services, Inc.
  • Biocon Limited - Preclinical, 2016
  • Biocon Limited - Pipeline by Indication, 2016

Today, cancer is the cause of ' one in seven' deaths worldwide, while diabetes now affects nearly ' one in ##' adults globally.

  • Insulin
  • Therapy
  • World
  • Product Initiative
  • Biocon Limited
  • Biocon Ltd - Business Description

The company reported one pharmaceuticals & healthcare deal each in 2016 and 2017.

  • Biosimilar
  • Insulin
  • India
  • Company Financials
  • Biocon Limited
  • 4.3.6. DISTRIBUTION BY DOSING FREQUENCY
  • Type of Molecule

OVERVIEW NEULASTA (PEGFILGRASTIM) IS COMPOSED OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) OR FILGRASTIM CONJUGATED TO MONOMETHOXYPOLYETHYLENE GLYCOL.

  • Insulin
  • North America
  • United States
  • Company
  • Market Size

One unit refers to one reusable insulin pen.

  • Insulin
  • India
  • South Asia
  • Market Size
  • Biocon Limited

One insulin pen has been considered as one unit.

  • Insulin
  • Medical Device
  • United States
  • Demand
  • GlobalData's company

The company offers products such as sevelamer, ciprofloxacin, amitryptyline, erythropoietin, filgrastim, follicle stimulating hormone (FSH), rituximab, ampicillin, albendazole, benezepril, and caprofen, among others.

  • Biopharmaceutical
  • Insulin
  • North America
  • United States
  • Company

The company offers products such as sevelamer, ciprofloxacin, amitriptyline, erythropoietin, filgrastim, follicle stimulating hormone (FSH), rituximab, ampicillin, albendazole, benezepril, and caprofen, among others.

  • Biopharmaceutical
  • Insulin
  • North America
  • United States
  • Company
  • GLOBAL FORECAST TO 2019

Q. ##.

  • Insulin
  • North America
  • United States
  • Market Size
  • Novo Nordisk Group